Healthcare provider profile · identity verified

Cheryl Whittaker, APRN

Nurse Practitioner · COLUMBIA, SC · NPI 1306418207

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	238	43
Atorvastatin Calcium	Atorvastatin Calcium	215	40
Pantoprazole Sodium	Pantoprazole Sodium	211	41
Rexulti	Brexpiprazole	153	suppressed
Eliquis	Apixaban	150	17
Metformin Hcl	Metformin Hcl	132	26
Lorazepam	Lorazepam	127	18
Losartan Potassium	Losartan Potassium	113	20
Gabapentin	Gabapentin	108	15
Mirtazapine	Mirtazapine	106	19
Levetiracetam	Levetiracetam	100	14
Trazodone Hcl	Trazodone Hcl	96	11
Donepezil Hcl	Donepezil Hcl	92	11
Divalproex Sodium	Divalproex Sodium	91	14
Levothyroxine Sodium	Levothyroxine Sodium	90	17
Tamsulosin Hcl	Tamsulosin Hcl	84	17
Memantine Hcl	Memantine Hcl	82	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	82	11
Furosemide	Furosemide	81	19
Rosuvastatin Calcium	Rosuvastatin Calcium	80	15
Lisinopril	Lisinopril	78	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	76	14
Metoprolol Succinate	Metoprolol Succinate	76	12
Latanoprost	Latanoprost	71	15
Pregabalin	Pregabalin	68	suppressed
Risperidone	Risperidone	53	12
Sertraline Hcl	Sertraline Hcl	50	11
Potassium Chloride	Potassium Chloride	49	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	47	suppressed
Trulicity	Dulaglutide	47	suppressed
Montelukast Sodium	Montelukast Sodium	45	suppressed
Buspirone Hcl	Buspirone Hcl	39	suppressed
Carvedilol	Carvedilol	37	suppressed
Ondansetron Odt	Ondansetron	37	20
Benztropine Mesylate	Benztropine Mesylate	36	suppressed
Hydralazine Hcl	Hydralazine Hcl	36	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	34	33
Citalopram Hbr	Citalopram Hydrobromide	34	suppressed
Clonazepam	Clonazepam	33	suppressed
Xarelto	Rivaroxaban	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Clopidogrel	Clopidogrel Bisulfate	31	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	31	suppressed
Nifedipine Er	Nifedipine	31	suppressed
Meloxicam	Meloxicam	29	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	28	suppressed
Humalog Kwikpen U-100	Insulin Lispro	28	suppressed
Incruse Ellipta	Umeclidinium Bromide	28	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	28	12
Omeprazole	Omeprazole	28	suppressed
Lacosamide	Lacosamide	27	suppressed
Symbicort	Budesonide/Formoterol Fumarate	27	suppressed
Januvia	Sitagliptin Phosphate	26	suppressed
Cephalexin	Cephalexin	25	17
Clonidine	Clonidine	24	suppressed
Ozempic	Semaglutide	24	suppressed
Sucralfate	Sucralfate	24	suppressed
Clomipramine Hcl	Clomipramine Hcl	23	suppressed
Clozapine	Clozapine	23	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	23	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	23	16
Nuplazid	Pimavanserin Tartrate	23	suppressed
Oxycodone Hcl	Oxycodone Hcl	23	suppressed
Prednisone	Prednisone	23	suppressed
Ingrezza	Valbenazine Tosylate	22	suppressed
Ibuprofen	Ibuprofen	21	suppressed
Namzaric	Memantine Hcl/Donepezil Hcl	21	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Digoxin	Digoxin	20	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	20	suppressed
Tramadol Hcl	Tramadol Hcl	20	suppressed
Acetazolamide	Acetazolamide	19	suppressed
Haloperidol	Haloperidol	19	suppressed
Lactulose	Lactulose	19	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	19	suppressed
Baclofen	Baclofen	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Novolog Flexpen	Insulin Aspart	18	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	18	suppressed
Sodium Chloride	0.9 % Sodium Chloride	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Invega Sustenna	Paliperidone Palmitate	16	suppressed
Klayesta	Nystatin	16	suppressed
Myrbetriq	Mirabegron	16	suppressed
Albuterol Sulfate	Albuterol Sulfate	15	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	15	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	15	suppressed
Bupropion Hcl	Bupropion Hcl	15	suppressed
Celecoxib	Celecoxib	15	suppressed
Finasteride	Finasteride	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Lithium Carbonate	Lithium Carbonate	14	suppressed
Memantine Hcl Er	Memantine Hcl	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Torsemide	Torsemide	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Haloperidol Lactate	Haloperidol Lactate	13	suppressed
Midodrine Hcl	Midodrine Hcl	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	13	suppressed
Glycopyrrolate	Glycopyrrolate	12	suppressed
Nystatin	Nystatin	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	12	suppressed
Selegiline Hcl	Selegiline Hcl	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	11	suppressed
Lanthanum Carbonate	Lanthanum Carbonate	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Yupelri	Revefenacin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error